Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FREQ.............................https://stockcharts.com/h-sc/ui?s=FREQ&p=W&b=5&g=0&id=p86431144783
THER STOCK..WILL JUMP SAME WAY
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
$FREQ - Up 47% Pre-Market/ Current Price $0.59.
Korro Bio and Frequency Therapeutics Announce Merger Agreement
$170m Ample Cash runway till '26
To Trade as $KRRO
Expected to close Q4 '23
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs
Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation
[color=red] Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026
WHAT IS THE SHARES STRUCTURE[t][color=red][/color][/t][/color]
Very nice close today!
I got filled .70 to .77
Quick 10%
Shares of Frequency Therapeutics Inc. lost more than three-fourths of their value and hit an all-time low in early trading Monday after the regenerative-medicine company scrapped its lead program following a Phase 2b study failure.
Frequency said it is ending development of FX-322 after the drug candidate missed the primary and secondary endpoints in the study in individuals with acquired sensorineural hearing loss, a type of hearing loss that occurs from damage to the inner ear.
The Lexington, Mass., company also threw in the towel on FX-345, a second candidate to treat sensorineural hearing loss, and said it would cut its workforce by 55% in a restructuring.
Frequency said it now plans to focus on remyelination program for multiple sclerosis and to explore strategic financing alternatives, adding that it expects the restructuring will extend its current cash runway into 2025.
Frequency shares were recently changing hands at an all-time low of 85 cents, down 78%, after falling to 70 cents, their lowest level since the company went public in October 2019, early in the session.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2023 09:52 ET (14:52 GMT)
Ah, freak out!
Le freak, c'est chic
Freak out!…
Source: Musixmatch
Glad I never got in
Totally went under the Ihub radar
Ouch. This didn’t age well.
In their 30 years of existence, Regeneron rarely has ever acquired a company. Its just not their M.O so it seems unlikely they would make a move on FREQ.
Heard on the street,
FREQ would be a perfect fit for REGN
* * $FREQ Video Chart 04-07-2021 * *
Link to Video - click here to watch the technical chart video
Bought some on recent drop $8.55 area..holding..adding more under $8 if that happens
$FREQ: Sitting on $224Million in CASH
At $9/sh right now........... trading WELllllllllllllll below Cash/share.
Wellllllllllllllllll below.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-freq/frequency-therapeutics/news/were-not-worried-about-frequency-therapeutics-nasdaqfreq-cas
GO $FREQ
$FREQ: March 2021 Investor Presentation
Now atrading at $8.70/sh
Dropped from $35 yesterday
https://investors.frequencytx.com/static-files/4a540e6b-b160-4e35-b487-5c82d264103b
GO $FREQ
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27
|
Created
|
03/23/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |